12 research outputs found

    Characterization of CytLEK1 as a Novel Regulator of the LIS1 Pathway

    Get PDF

    Nonantithrombotic Medical Options in Acute Coronary Syndromes: Old Agents and New Lines on the Horizon

    Get PDF
    Acute coronary syndromes (ACS) constitute a spectrum of clinical presentations ranging from unstable angina and non-ST-segment elevation myocardial infarction to ST-segment myocardial infarction. Myocardial ischemia in this context occurs as a result of an abrupt decrease in coronary blood flow and resultant imbalance in the myocardial oxygen supply-demand relationship. Coronary blood flow is further compromised by other mechanisms that increase coronary vascular resistance or reduce coronary driving pressure. The goals of treatment are to decrease myocardial oxygen demand, increase coronary blood flow and oxygen supply, and limit myocardial injury. Treatments are generally divided into “disease-modifying” agents or interventions that improve hard clinical outcomes and other strategies that can reduce ischemia. In addition to traditional drugs such as beta-blockers and inhibitors of the reninangiotensin-aldosterone system, newer agents have expanded the number of molecular pathways targeted for treatment of ACS. Ranolazine, trimetazidine, nicorandil, and ivabradine are medications that have been shown to reduce myocardial ischemia through diverse mechanisms and have been tested in limited fashion in patients with ACS. Attenuating the no-reflow phenomenon and reducing the injury compounded by acute reperfusion after a period of coronary occlusion are active areas of research. Additionally, interventions aimed at ischemic pre- and post-conditioning may be useful means by which to limit myocardial infarct size. Trials are also underway to examine altered metabolic and oxygen-related pathways in ACS. This review will discuss traditional and newer anti-ischemic therapies for patients with ACS, exclusive of revascularization, anti-thrombotic agents, and the use of high-intensity statins

    The Impact of COVID-19 on Cardiovascular Training Programs: Challenges, Responsibilities and Opportunities

    No full text
    The Covid-19 pandemic has dramatically disrupted cardiovascular disease (CVD) fellowship training. Significant reductions in cardiac volumes and simultaneous reassignment of physicians, including to Covid-centric services, have led to educational challenges in fellowship programs and disruptions to trainee experiential learning. While the initial response focused on preparedness for the anticipated surge, it is now critical to focus on the impact on training in this new era. Flexibility and innovation are needed in this highly volatile environment. Programs must respond to these changes with an eye towards providing a high quality educational experience while maintaining wellness and professional growth of fellows in training (FITs). This document seeks to chronicle the current state of CVD training and explore opportunities for response to this evolving environment
    corecore